Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $7000.0.

  • Biodesix's Asset Writedowns and Impairment changed N/A to $7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $209000.0, marking a year-over-year increase of 25833.33%. This contributed to the annual value of $238000.0 for FY2024, which is 1900.0% up from last year.
  • Per Biodesix's latest filing, its Asset Writedowns and Impairment stood at $7000.0 for Q3 2025.
  • In the past 5 years, Biodesix's Asset Writedowns and Impairment registered a high of $400000.0 during Q1 2022, and its lowest value of -$267000.0 during Q4 2023.
  • Over the past 5 years, Biodesix's median Asset Writedowns and Impairment value was $100000.0 (recorded in 2023), while the average stood at $109533.3.
  • As far as peak fluctuations go, Biodesix's Asset Writedowns and Impairment skyrocketed by 653333.33% in 2021, and later crashed by 48695.65% in 2023.
  • Over the past 5 years, Biodesix's Asset Writedowns and Impairment (Quarter) stood at $193000.0 in 2021, then crashed by 64.25% to $69000.0 in 2022, then crashed by 486.96% to -$267000.0 in 2023, then surged by 138.58% to $103000.0 in 2024, then plummeted by 93.2% to $7000.0 in 2025.
  • Its last three reported values are $7000.0 in Q3 2025, $26000.0 for Q2 2025, and $73000.0 during Q1 2025.